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TCT-121
Thoracic Aortic Pseudoaneurysm Following Endovascular Stent Graft
Placement for Treatment of Type B Dissection: What causes it?
Rolf Alexander Janosi1, Markus Bettin1, Thomas Konorza1, Holger Eggebrecht2,
Raimund Erbel1
1West-German Heart Center Essen, Essen, Germany, 2Cardioangiological Center
Bethanien, Essen, Germany
Background: To analyze early technical success and late clinical success after endovas-
cular entry sealing for chronic type B dissection with special emphasis on the develop-
ment of pseudoaneurysm, reintervention, false lumen and aortic remodeling.
Methods: Retrospective analysis of a prospective database. We observed 151 patients
(mean age 62,2 12,6 years, 67% male) in the period July 1999 to May 2010 with acute
or chronic type B dissection treated by endovascular entry sealing. Serial contrast-
enhanced computed tomography (CT) scans of 151 type B dissection patients (mean age
62,2  12,6 years, 67% male) who underwent TEVAR were analyzed. True and false
lumen diameter at baseline and follow-up were quantified. In 6 of 8 patients with
pseudoaneurysm a complete follow-Up by CT was available which was compared with
the other 143 patients: The angle between distal stent ending and the further aorta in
patients without and with pseudoaneurysm was measured.
Results: Eight of 151 patients developed a distal pseudoaneurysm after TEVAR. The
incidence of development of pseudoaneurysm after TEVAR was 5.3 %. Seven patients
were treated by distal extension of the stent graft, one denied reintervention. There was a
significant difference in the angle between distal stent ending and the further aorta in
patients without and with pseudoaneurysm (167,1°  12,4 vs. 148,2°  16,5, p 0,05).
In mean a pseudoaneurysm was diagnosed after 22,5 months (3,2-115,2 months). By
TEVAR an aortic remodeling was achieved with a significant gain of the true lumen (1,6
 0,8 cm vs. 2,9  0,5 cm, p  0,001).
Conclusions: Endovascular treatment in chronic type B dissection has a high technical
success rate and low mortality. Pseudoaneurysm of the thoracic aorta following endovas-
cular stent graft placement is a rare and potentially fatal condition.
TCT-122
Endovascular Stent-Graft Implantation in Patients with Unstable Acute
Intramural Hematoma: Is Endovascular Repair For Intramural Hematoma
Over-Treatment or Suitable Treatment?
Hyunmin Choi1, Woo-Ik Jang1, June Namgung1
1Inje University College of Medicine, Ilsan Paik Hospital, Goyang, Gyeonggi
Background: Endovascular aortic repair (EVAR) by using stent-graft is becoming one
of the important therapeutic options for Stanford type B acute aortic syndrome. However,
there is no valid or accepted indication of EVAR in Stanford type B intramural hematoma
(IMH), even unstable features such as extra-aortic blood leak, refractory pain and very
thick hematoma (11 mm) with ulceration because of uncertain role of EVAR.
Methods: We reviewed 18 patients who underwent EVAR due to Stanford type B
unstable IMH from January 2007 to December 2010. Indications of EVAR were
extra-aortic blood leak, refractory pain despite medical therapy and very thick hematoma
(11 mm) with ulceration. Target points of stent-graft were definite point of extra-aortic
blood leak, maximally thickened hematoma with or without ulceration lesions. Compared
with baseline findings, we analyzed the changes in proximal and distal axial reference
diameter, minimal and maximal axial diameter of lesion and maximal axial thickness of
IMH at 12-month after EVAR by using multidetector computed tomography (MDCT). In
follow-up MDCT, we defined 75% reduction in maximal axial thickness of IMH after
EVAR as good, from 26 to 74% as fair and 25% as no reduction.
Results: Mean follow-up duration was 17.5 months and follow-up rate of MDCT was
94.4% (n17). The incidence of each reduction criteria was good in 64.7% (n11), fair
in 29.4% (n5) and no in 5.9% (n1) respectively. Maximal axial diameter got smaller
(mean 14.2  10.6% decrement) and minimal axial diameter increased (mean 33.2 
17.3% increment) after EVAR.
Conclusions: EVAR promotes the reduction of main aortic pathologies through
hematoma absorption. EVAR may assist not only appropriate positive remodeling but
also negative remodeling in pathologic lesion of IMH. Although there is no approved or
standard guideline, EVAR is an advantageous treatment to provide a good endurance
against secondary structural weakening due to IMH.
TCT-123
Initial Experience of Chimney Technique in Case of Aortic Arch Pathologies
Involving the Supra-Aortic Branches
Renat Akchurin1, Timur Imaev2, Alexey Komlev1, Peter Lepilin2, Midat Osmanov2,
Alexander Kolegaev2, Ilya Pokidkin2
1Russian Cardiology Research Center, Moscow, Moscow, 2Russian Cardiology
Research Center, Moscow, Russian Federation
Background: We present our initial clinical experience with chimney technique in the
endovascular repair of aortic arch pathologies involving the supra-aortic branches. In case
of thoracic endovascular aortic repair (TEVAR) it’s very important to achieve adequate
proximal zone, so the endoprosthesis often need to cover aortic arch branches. Chimney
grafts have been proposed to preserve flow into over stented aortic branches during
TEVAR.
Methods: Ten patients underwent TEVAR combined with a chimney graft implantation
between January 2012 and June 2012. 6 patients were with aortic arch aneurysms and 4
patients with complicated type B dissection. In all cases chimney graft was implanted into
the left subclavian artery. Mean length of follow up was up to 6 months.
Results: All chimney grafts were successfully implanted. In postoperative and follow up
period no cases of endoleaks were found, there were no cases of paraplegia. No other
postoperative aneurysm expansion has occurred and the chimney grafts remain patent.
The overall 30-day mortality was 0%.
Conclusions: Chimney technique is promising option in case of urgent TEVAR in
patients with an inadequate proximal neck and is a real alternative to fenestrated and
branched endoprostheses.
TCT-124
Endovascular Repair of Abdominal and Iliac Aneurysm Repair with
Preservation of Pelvic Flow
Patick Kelly1, Laura Danielson2, Madeline Nykamp2, Angelo Santos3,
Greg Schultz1, Chad Laurich1, Spencer Schilling1
1Sanford Health, Sioux Falls, SD, 2Stanford Health, N/A, 3Sanford Health, N/A
Background: Preservation of pelvic flow with an endovascular approach to common
iliac aneurysms.
Methods: We constructed a bifurcated iliac limb by sewing a 12-mm and an 8-mm
covered stent graft directly to a 20-mm stent graft limb, deployed ex-vivo. We left the
distal ends of the 12-mm and 8-mm graft free to allow for more flexibility and greater ease
of selection of the 8-mm internal iliac limb. Once the graft is re-sheathed via spiral wire
technique, it is inserted, orientated, positioned 3-4cm above the ostium of the internal iliac,
then deployed. With the main retrograde wire passing through the 12-mm graft, and the
free 8-mm limb was then accessed from an arm approach. Angiograms and measurements
are made and a covered self-expanding stent graft is deployed. The 12-mm limb is used
to extend the graft into the external iliac, completing exclusion of the common iliac
aneurysm, with preservation of both the internal and external iliac arteries.
Results: Thus far, we have performed this procedure on five patients since April 2011,
and all have done extremely well. All have been men, who have been able to maintain
appropriate exercise tolerance and remain free from erectile dysfunction.
Conclusions: Bifurcated limb stent grafts appear to be a viable endovascular treatment
for large common iliac aneurysm, while maintaining good pelvic blood flow and all the
advantages ensuing.
TCT-125
A Novel Antimicrobial-Bonded Aortic Graft for Aortic Graft Infection
Ibrahim Aboshady1, Issam Raad2, L. Maximilian Buja3, Kamal Khalil3
1Texas Heart Institute, Houston, TX, 2The University of Texas MD Anderson
Cancer Center, Houston, TX, 3The University of Texas HSC, Houston, TX
Background: Vascular aortic infection is a serious complication after arterial surgery.
We hypothesize that bonding 3 antimicrobial agents to aortic grafts would prevent/
minimize perioperative vascular graft infections in a pig model for at least 6 months
postoperatively.
Methods: In the pilot study, vascular Dacron grafts, 6 mm in diameter, were surgically
implanted in the infrarenal portion of the abdominal aorta of 6 Sinclair Miniature swine.
Two pigs received a graft that had been bonded with 60 mg/mL solutions of rifampin and
minocycline; the other 4 pigs received unbonded grafts. Before implantation, the 2 bonded
grafts and 2 of the 4 unbonded grafts were immersed in 2 mL of a bacterial solution
containing 1 to 2107 colony-forming units (CFU)/mL of S. aureus (ATCC 29213) for
15 minutes. Two weeks after graft implantation, the pigs were sacrificed and the grafts
were surgically excised for study. Clinical, microbiological, and histopathologic data were
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correlated. Eighteen animals have been studied have been studies to assess the rate of
depreciation of the drugs over 6 months’ duration.
Results: Whereas specimens of the 2 S. aureus-treated unbonded grafts had high bacterial
counts (6.25106 and 1.38107 CFU/graft), specimens of the 2 S. aureus-treated bonded
grafts showed no bacterial growth. Bacterial growth in the 2 control pigs’ grafts (1.8103
and 7.27103 CFU/graft) reflected direct accidental perioperative bacterial contamina-
tion; the organisms isolated were not S. aureus (S. cohnii spp urealyticus and S.
chromogenes). The histopathologic and clinical data confirmed the microbiological
findings. Only pigs that received unbonded grafts showed histopathologic evidence of
perigraft abscess.
Conclusions: The quantitative results of our studies showed that bonding 3 antimicrobial
agents to aortic grafts prevented aortic graft infection by synergistically prolonging
antistaphylococcal activity. After the safety and preventive effect of this graft have been
further assessed, its use may be recommended for the in situ replacement of infected grafts
and possibly for routine primary cases, especially in immunocompromised patients,
patients with a hostile abdomen, and patients undergoing redo procedures.
TCT-126
Endurant US Pivotal Trial: 2-year outcomes
Michel Makaroun1, Michael Tuchek2, Doug Massop3, John Henretta4, Brij Maini5
1UPMC, Pittsburg, PA, 2Loyola University Medical Center, Chicago, IL, 3The
Iowa Clinic, West Des Moines, IA, 4Mission Hospital, Asheville, NC,
5PinnacleHealth Cardiovascular Institute, Wormleysburg, PA
Background: This study reports the 2-year outcomes of the United States (US)
regulatory trial of the Endurant Stent Graft System (Medtronic Vascular, Santa Rosa, CA)
for the treatment of abdominal aortic aneurysms (AAA).
Methods: This was a prospective, single arm, multicenter trial conducted at 26 sites in the
US. From April 2008 to May 2009, 150 patients with AAA were treated with the
Endurant bifurcated stent graft. The main inclusion criteria were an AAA diameter 5
cm, proximal neck length 10 mm, bilateral iliac fixation length 15 mm, and a neck
angulation of60 degrees. The primary safety endpoint was freedom from major adverse
events at 30 days. The primary effectiveness endpoint was successful aneurysm treatment
at 12 months. Two years results are site reported.
Results: One hundred forty-nine patients (99.3%) had a successful implantation of the
Endurant stent graft. The one failure was due to the inability to cannulate the contralateral
gate. Patients within this trial were mostly male (91.3%), with a mean age of 73.1 and who
had significant comorbidities. Mean estimated blood loss was 185 mL (range, 0-1450 ml),
with one patient requiring a blood transfusion. The average hospital stay was 2.1 days.
Through the 24 month follow up, there were no ruptures, migrations or conversions to
open repair. The technical observations found no graft kinking or twisting, and no
fractures. A total of two (1.5%) stent graft occlusions were observed at the 2 year
follow-up. There were no type I or type III endoleaks observed at 24 months. Aneurysm
sac diameter decreased greater than 5mm occurred in 60.8% of patients and remained
stable in 36.9% of patients. There were only three patients (2.3%) that had an increase sac
of more than 5mm. There were no aneurysm related deaths (100% Freedom from ARM)
through two years.
Conclusions: The two year results of this pivotal trial continue to show that the Endurant
Stent Graft is a safe, durable, and effective device for the treatment of abdominal aortic
aneurysms.
TCT-127
The Impact of Later Generation Thoracic Aortic Stent Grafts as
Demonstrated in the VALOR II Trial
Zvonimir Krajcer1, Michael Tuchek2, Anthony Lee3, Rod White4, Manish Mehta5,
Sean Lyden6, Dipankur Mukherjee7, Joseph Bavaria8, Ronald Fairman8
1THI, Baylor Clllege of Medicine, Houston, TX, 2Loyola University Medical
Center, Chicago, IL, 3Surgical Associates of Palm Beach County, Boca Raton, FL,
4Harbor-UCLA Medical Center, Torrance, CA, 5Albany Medical Center, Albany,
NY, 6Cleveland Clinic Foundation, Cleveland, OH, 7Inova Fairfax Hospital,
Fairfax, VA, 8Hospital of the University of Pennsylvania, Philadelphia, PA
Background: Improvements in technique and devices promise improved outcomes
following endovascular repair of aneurysms of the descending thoracic aortic. This
mid-term report provides an update to the VALOR II trial results.
Methods: VALOR II is a prospective, multicenter, observational study of endovascular
treatment with the Valiant thoracic stent graft (Medtronic Endovascular Therapies, Santa
Rosa, Calif) in patients with descending thoracic aortic aneurysms (TAA) of degenerative
etiology.
Results: VALOR II enrolled 160 patients between December 2006 to September 2009
and 1-year results have been previously reported. In this update, follow-up was available
on 72% of patients through 3 years. One additional aneurysm-related death occurred after
1 year. One conversion to surgery was performed at 3 years in a patient who had
continued aneurysm expansion in the absence of any observable endoleak. Seven
secondary stent graft procedures were performed in 6 patients; 1 in the first 30 days, 3 after
1 year and 3 after 2 years. Freedom from secondary stent graft procedures was 94.9% at
3 years (95% CI: 88.8%-97.7%), which compared favorably with the earlier VALOR trial
(85.1% at 3 years; 95% CI: 78.5%-89.8%), a study of the Talent thoracic stent graft with
similar objectives and inclusion criteria. There was no type I or III endoleak reported at
2 or 3 years.
Conclusions: Mid-term results with the Valiant thoracic stent graft are acceptable and
compare favorably to an older generation device implanted in an earlier series of similar
patients. Long term results are needed to confirm this positive trend.
TCT-128
Disruptive Endovascular Technology with Multilayer Flow Modulator Stents
(MFM) as a Therapeutic Option in the Management of Thoraco-abdominal
Aortic Aneurysms. Early results from MFM Registry.
Sherif Sultan1, Niamh Hynes2
1Western Vascular Institute, Galway, — Please Select —, 2Western Vascular
Institute, Galway, Ireland
Background: Out of 172 cases implanted worldwide we present the first 26 cases that
were scrutinized. All were Crawford thoraco-abdomial AAA. 75% were male with
median age of 73. Mean aneurysm diameter was 67mm with mean length of 167mm.
79.7% were ASA IV E. 62 % were redo after previous TEVAR.
Methods: Primary Endpoints are Freedom from Rupture and Aneurysm-related Death,
Aneurysm Sac and Lumen Volume Modulation, Patency of Visceral Branches, and
Freedom from Stroke and Paraplegia. Secondary Endpoints were technical success and
all-cause mortality. Finite Element Analyses was achieved on aortic sac pressure, shear
stress, wall displacement and blood flow velocities. All stents were deployed to their
intended target. No Aneurysm-related death occurred within 18 Months. No peri-
operative Visceral or Renal insult occurred. There were no Cerebro-vascular accidents,
paraplegia or loss of visceral branches patency. Two patients required reintervention
because of device foreshortening.
Results: At 6 months there was decline in average total sac volume, thrombus volume
and average diameter. Mean sac volume shrunk by 8% with lumen volume reduction of
14%. Average thrombus volume increased but thrombus to lumen ratio decreased by
23%. Finite Element Analysis post MFM documented dampening of wall displacement
by 80% with immediate depressurization of the aortic sac and dissipation of the maximum
pressure zone. There was 55% immediate reduction in Wall Stress.
Conclusions: MFM carries no risk of critical shuttering or loss of native side branches.
MFM offers immense promise for resolution of complex thoraco-abdominal aneurysms.
A Global MFM Registry is required and long-term follow-up is mandatory.
TCT-129
Contemporary comparison of the Paradigm Shift in Rupture AAA
Management; Twelve years experience in a tertiary referral centre of
Endovascular repair of RAAA(REVAR) vs open repair (OR)
Sherif Sultan1, Allaa ElHelaly2, Niamh Hynes2
1Western Vascular Institute, Galway, — Please Select —, 2Western Vascular
Institute, Galway, Ireland
Background: Out of 683 AAA operated upon, 120 patients presented with RAAA over
12 years, 42 had REVAR and 78 had OR.
Methods: Parallel Group comparison.
Results: Mean length of ICU was halved with REVAR VS OR (P0.008). Blood
product requirements were 60% less in REVAR (P0.0001). The Risk of ARDS and
cardiac events were doubled if OR were performed .However there were no statistical
significance in acute renal injury. Mean length of hospital stay was 7	/3 days for
REVAR , and 12	/6 for OR (P0.042).Thirty day mortality was 16% for REVAR vs
32% for OR ( P0.001). Total Emergency mortality rate decreased from 64% to 28.2%.
we attributed the Low Mortality Rate of 16%for REVAR Vs 32%in OR was due to
introduction of an REVAR Programme which constitutes screening for prevention with
early intervention and REVAR for rupture which has an absolute perioperative mortality
reduction of 49% over OR. 5 years Survival of Patients with RAAA were 75% REVAR
vs. 60% OR (p0.0205). During 20th century 95% of all AAA were done surgically.
However during 21st century 80% of AAA is done endovascularly. Mean Annual number
of OR dropped (P0.845) however Mean Annual number of EVARs had rocketed
(P0.006) . Overall number of AAA repairs has increased by 65% over twelve year’s
period but the absolute number of RAAA had declined by 24%.
Conclusions: Para-Millennium and Contemporary Trends in AAA Management had
shown Increased in Elective EVAR which increased the mortality advantage in favour of
REVAR and it should be the Gold standard for RAAA.
TCT-130
Clinical Efficacy and Cost per Quality-Adjusted –Life Years with Pararenal
Endovascular Aortic Repair (PEVAR) for Para-renal AAA compared with
Open Surgical Repair.
Sherif Sultan1, Niamh Hynes2
1Western Vascular Institute, Galway, — Please Select —, 2Western Vascular
Institute, Galway, Ireland
Background: EVAR affords more propitious peri-operative and long-term survival than
Open Surgical Repair (OSR). However, up to 70% of AAAs are anatomically incompat-
ible with EVAR.
Methods: We aim to gauge the feasibility of applying commercially-available endografts
to pararenal aneurysms compared with OSR. Primary endpoints were aneurysm-related
survival and cost per Quality-Adjusted–Life-Years (QALY). From 2002-2009, 1868
patients with pararenal AAA were investigated. 118 had intervention and were described
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